Modified RNA encoding VEGF-A polypeptides, formulations, and uses relating thereto

Patent metadata

Field	Value
Publication number	US-11866475-B2
Application number	US-201716305224-A
Country	US
Kind code	B2
Filing date	Jun 6, 2017
Priority date	Jun 7, 2016
Publication date	Jan 9, 2024
Grant date	Jan 9, 2024

Abstract

The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.

First claim

What is claimed is:

1. A composition comprising a modified mRNA encoding a VEGF-A polypeptide of SEQ ID NO: 2 and a citrate saline buffer, wherein the citrate saline buffer is substantially free of divalent cations.

2. The composition of claim 1 , wherein the composition does not include a lipid-based complex.

3. The composition of claim 1 , wherein the composition does not include a lipid-based complex nor calcium.

4. A formulation comprising a pharmaceutically acceptable amount of a modified mRNA encoding a VEGF-A polypeptide of SEQ ID NO: 2 and a citrate saline buffer, wherein the citrate saline buffer is substantially free of divalent cations.

5. The formulation of claim 4 , wherein the citrate saline buffer is substantially free of calcium and magnesium.

6. The formulation of claim 4 , wherein the citrate saline buffer contains no calcium or magnesium.

7. The formulation of claim 4 , further comprising a pharmaceutically acceptable excipient.

8. The formulation of claim 7 , wherein the pharmaceutically acceptable excipient is a solvent, dispersion medium, diluent, dispersion, suspension aid, surface active agent, isotonic agent, thickening or emulsifying agent, preservative, core-shell nanoparticle, polymer, peptide, protein, cell, hyaluronidase, or mixture thereof.

9. The formulation of claim 4 , wherein the formulation does not include a lipid-based complex.

10. The formulation of claim 4 , wherein the formulation does not include a lipid-based complex nor calcium.

11. A method of treating a human subject suffering from a disease responsive to VEGF-A therapy, comprising administering to the human subject the composition according to claim 1 .

12. The method of claim 11 , wherein the citrate saline buffer is substantially free of calcium and magnesium.

13. The method of claim 11 , wherein the citrate saline buffer contains no calcium or magnesium.

14. The method of claim 11 , wherein the composition further comprises a pharmaceutically acceptable excipient.

15. The method of claim 14 , wherein the pharmaceutically acceptable excipient is a solvent, dispersion medium, diluent, dispersion, suspension aid, surface active agent, isotonic agent, thickening or emulsifying agent, preservative, core-shell nanoparticle, polymer, peptide, protein, cell, hyaluronidase, or mixture thereof.

16. The method of claim 11 , wherein the disease is heart failure with reduced or preserved ejection fraction, kidney disease, a disease involving skin grafting and tissue grafting, post-MI cardiac dysfunction, ischemic heart disease, a vascular injury from trauma or surgery, a skin ulcer including a diabetic ulcer, critical limb ischemia, pulmonary hypertension, or peripheral arterial disease.

17. The method of claim 11 , wherein the composition is administered to the human subject via an intramuscular route, via an intradermal route, via a subcutaneous route, via an intracardial route, via an epicardial route, through a portal vein catheter, through a coronary sinus catheter, or by direct administration into the area to be treated.

18. The method of claim 11 , wherein the composition is administered to the human subject at a fixed-dosage in multiple administrations.

19. The method of claim 11 , wherein the composition is administered to the human subject via an intracardial route, via an epicardial route, through a portal vein catheter, or through a coronary sinus catheter, and at a fixed-dosage in multiple administrations.

20. The method of claim 11 , wherein the composition is administered to the human subject by direct administration into the area to be treated at a fixed-dosage in multiple administrations.

21. The method of claim 11 , wherein the composition comprises a concentration of the modified mRNA of between 0.1 and 1 μg/μL formulated in the citrate saline buffer.

22. The method of claim 11 , wherein the composition comprises a concentration of the modified mRNA of between 1 and 10 μg/μL formulated in the citrate saline buffer.

23. The method of claim 11 , wherein the composition comprises a concentration of the modified mRNA of between 10 and 50 μg/μL formulated in the citrate saline buffer.

24. The method of claim 11 , wherein the composition comprising the citrate saline buffer is less toxic to the human subject than a lipid-based composition or formulation.

25. The method of claim 11 , wherein the composition does not include a lipid-based complex.

26. The method of claim 11 , wherein the composition does not include a lipid-based complex nor calcium.

Assignees

• Modernatx Inc

Inventors

• Parinder Leif Karlsson
• Fritsche Danielson Regina Desirée
• Hansson Kenny Mikael
• Gan Li Ming
• Clarke Jonathan
• Egnell Ann-Charlotte Eva
• Chien Kenneth Randall

Classifications

• C07K14/515 Primary

  Angiogenesic factors; Angiogenin · CPC title

• A61K9/0019 Primary

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/0021

  Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title

• A61K31/712

  Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose · CPC title

• A61K38/1866

  Vascular endothelial growth factor [VEGF] · CPC title